Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Contents Foreword 522 1. Antihyperglycaemic treatment of type 2 diabetes mellitus 523 1.1 Oral antidiabetic drugs 523 1.1.1 Non-β-cytotropic oral antidiabetic drugs 523 1.1.1.1 Metformin 523 1.1.1.2 Alpha-glucosidase inhibitors (acarbose, miglitol) 526 1.1.1.3 PPAR-γ-ligands (rosiglitazone, pioglitazone) 528 1.1.1.4 Combination therapy with non-β-cytotropic oral antidiabetic drugs 531 1.1.2 β-cytotropic medications: potassium channel blockers 531 1.1.2.1 Sulphonylureas 531 1.1.2.2 Sulphonylurea analogues (repaglinide, nateglinide) 533 1.1.2.3 Combination therapy with non-β-cytotropic oral antidiabetic drugs 534 1.1.3 DPP-4 inhibitors 534 1.2. Injectable therapies 538 1.2.1 Incretin mimetics (exenatide) 538 1.2.2 Insulin therapy 539 1.2.2.1 Indication 539 1.2.2 2 Blood glucose self-monitoring 540 1.2.2.3 Application 540 1.2.2.4 Insulin administration 540 1.2.2.5 Conventional therapy 540 1.2.2.6 Intensified conventional insulin therapy 541 1.2.2.7 Combination treatment with insulin and oral antidiabetic drugs 541 1.2.2.8 Side-effects of insulin therapy 542 2. Flowchart of antihyperglycaemic treatment of type 2 diabetes 543 2.1 Legend to flowchart 544 3. References 545 4. Appendix 1: Statement by the DDG regarding the results of the ACCORD and ADVANCE trials 553 1 Note: This updated version takes into account all evidence that was published prior to the end of 06/2008, as well as all new approvals/indications prior to the same date.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“More-over, the 10-year follow-up data from the UKPDS which was published recently attests to the long-term bene fi ts of intensi-fi ed antihyperglycaemic therapy in reducing macrovascular end points such as myocardial infarction ( Holman et al., 2008, EC Ib ).”
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Self-citationEffect of a multifactorial intervention on mortality in type 2 diabetes
Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,465
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Metformin and reduced risk of cancer in diabetic patients
Evans, J. M. M., Donnelly, L. A., Emslie-Smith, A. M., Alessi, D. R., & Morris, A. D. (2005) · BMJ · doi:10.1136/bmj.38415.708634.f7 · Cited by 2,388
DeFronzo, R. A., Ratner, R. E., Han, J., Kim, D. D., Fineman, M. S., & Baron, A. D. (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1092 · Cited by 1,559
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
Cited by
Glucagon-like Peptide–1 Analogues for Type 2 Diabetes Mellitus: Current and Emerging Agents
Gallwitz, B. (2011) · Drugs · doi:10.2165/11592810-000000000-00000 · Cited by 142
Self-citationThe evolving place of incretin-based therapies in type 2 diabetes
Gallwitz, B. (2010) · Pediatric Nephrology · doi:10.1007/s00467-009-1435-z · Cited by 42
Self-citationKostev, K., Dippel, F.-W., & Rathmann, W. (2014) · Primary Care Diabetes · doi:10.1016/j.pcd.2013.10.001 · Cited by 35
Metadata
- Authors
- Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H.-U., Joost, H.-G., Kellerer, M., Kloos, C., Kunt, T., Nauck, M., Schernthaner, G., Siegel, E., & Thienel, F.
- Venue
- Experimental and Clinical Endocrinology & Diabetes
- Publisher
- Georg Thieme Verlag KG
- Published
- 2009-10
- Volume
- 117
- Issue
- 09
- Pages
- 522-557
- ISSN
- 0947-7349 (ISSN-L)
- 1439-3646
- OpenAlex
- W219049085
- Cited by
- 91
- References
- 42
- FWCI
- 8.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus. https://app.cochat.ai/papers/10.1055/s-0029-1239559
- The paper
- Matthaei, S., Bierwirth, R., Fritsche, A., Gallwitz, B., Häring, H.-U., Joost, H.-G., Kellerer, M., Kloos, C., Kunt, T., Nauck, M., Schernthaner, G., Siegel, E., & Thienel, F. (2009). Medical Antihyperglycaemic Treatment of Type 2 Diabetes Mellitus. Experimental and Clinical Endocrinology & Diabetes. https://doi.org/10.1055/s-0029-1239559
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.